Skip to main content
NVDA+0.14%AAPL+0.02%GOOGL-0.63%MSFT-0.03%AMZN+0.24%TSM-3.01%SPCX-4.19%META-0.23%AVGO-4.35%TSLA-0.03%SKHY-4.35%MU+0.17%BRK-B+0.95%LLY-1.61%AMD-3.90%JPM+0.56%WMT+2.22%ASMLa+1.27%V+0.81%XOM+2.75%JNJ-0.76%INTC-5.34%MA+0.82%0700.HK+1.97%ABBV+0.39%CSCO-2.13%1398.HK-0.69%CVX+3.12%COST+0.60%AP2d-0.09%AMAT-2.13%LRCX-2.71%ORCL-5.48%DELL-0.76%BAC+0.17%KO+2.27%CAT-2.17%PG+1.87%1816.HK-26.47%UNH-1.34%3988.HK+1.12%0005.HK+1.80%GE+0.66%HSBA.L-1.95%PM+4.05%0857.HK+0.20%0939.HK+0.85%NFLX+2.68%MS-1.20%HD+3.39%AUDCHF+0.57%EURAUD-0.52%EURCAD-0.50%AUDJPY+0.46%CADCHF+0.46%USDTRY+0.44%GBPTRY+0.41%CADJPY+0.38%GBPAUD-0.33%USDZAR-0.33%GBPHKD+0.32%GBPMXN-0.28%AUDUSD+0.28%EURNZD-0.28%GBPCAD-0.26%GBPZAR-0.26%NZDCHF+0.26%USDCAD-0.25%EURUSD-0.24%AUDNZD+0.23%EURGBP-0.23%NOKJPY+0.23%PLNJPY+0.21%EURZAR-0.21%USDCHF+0.21%NZDCAD-0.20%GBPCHF+0.19%NZDJPY+0.19%SGDJPY+0.18%NZDSGD+0.16%USDILS+0.16%AUDSGD+0.15%NZDMXN+0.15%USDSEK-0.14%USDJPY+0.14%EURJPY-0.13%USDDKK-0.13%USDNOK-0.12%EURHKD+0.11%GBPJPY+0.11%USDPLN-0.10%AUDNOK+0.10%USDCNH-0.10%AUDDKK+0.09%CHFSGD+0.08%CHFJPY-0.07%USDMXN-0.07%USDSGD-0.07%GBPNZD-0.06%EURSGD+0.05%EURCHF-0.05%NZDUSD+0.05%USDTHB+0.04%USDCOP-0.04%EURCNH+0.04%EURCZK+0.03%EURSEK-0.03%CHFNOK+0.02%AUDCAD+0.02%EURPLN+0.01%GBPUSD-0.01%EURDKK-0.01%USDHKD+0.01%EURNOK0.00%GBPSGD0.00%CHFSEK0.00%XPTUSD+2.04%GAGUSD+1.71%XAGUSD+1.71%HG1+1.44%GAUUSD+1.11%XAUUSD+1.11%UKOIL-1.04%USOIL-0.85%S1+0.74%COTTON+0.53%C1+0.50%W1+0.35%BTCUSD-1.08%ETHUSD+11.79%USDTUSD-0.05%XRPUSD+5.55%SOLUSD+1.82%TRXUSDT-0.91%ZECUSDT-8.35%DOGEUSD+5.25%XMRUSDT-2.57%LINKUSD+7.35%XLMUSD-2.95%BCHUSDT-7.05%LTCUSD+1.20%UNIUSD-6.89%SUIUSD-6.32%HBARUSDT-1.56%TONUSD+18.86%TAOUSDT-6.02%AAVEUSD-4.48%DOTUSDT+2.92%ICPUSDT-6.55%ONDOUSDT+1.49%WLDUSDT-5.81%JUPUSDT-2.55%ARBUSDT-4.80%ATOMUSDT+6.98%STXUSDT+6.42%INJUSDT-6.74%FETUSDT-4.14%PYTHUSDT+10.14%TIAUSDT+9.94%SEIUSDT-3.41%IMXUSDT+7.40%GRTUSDT-3.76%OPUSDT-0.41%WIFUSDT-8.72%IOTAUSDT-5.68%AXSUSDT-5.67%POLUSDT-2.74%FARTCOINUSDT+2.08%EOSUSDT-0.69%DYDXUSDT-0.09%GALAUSDT-4.26%ORDIUSDT-6.25%RONINUSDT-4.25%NOTUSDT-5.84%NVDA+0.14%AAPL+0.02%GOOGL-0.63%MSFT-0.03%AMZN+0.24%TSM-3.01%SPCX-4.19%META-0.23%AVGO-4.35%TSLA-0.03%SKHY-4.35%MU+0.17%BRK-B+0.95%LLY-1.61%AMD-3.90%JPM+0.56%WMT+2.22%ASMLa+1.27%V+0.81%XOM+2.75%JNJ-0.76%INTC-5.34%MA+0.82%0700.HK+1.97%ABBV+0.39%CSCO-2.13%1398.HK-0.69%CVX+3.12%COST+0.60%AP2d-0.09%AMAT-2.13%LRCX-2.71%ORCL-5.48%DELL-0.76%BAC+0.17%KO+2.27%CAT-2.17%PG+1.87%1816.HK-26.47%UNH-1.34%3988.HK+1.12%0005.HK+1.80%GE+0.66%HSBA.L-1.95%PM+4.05%0857.HK+0.20%0939.HK+0.85%NFLX+2.68%MS-1.20%HD+3.39%AUDCHF+0.57%EURAUD-0.52%EURCAD-0.50%AUDJPY+0.46%CADCHF+0.46%USDTRY+0.44%GBPTRY+0.41%CADJPY+0.38%GBPAUD-0.33%USDZAR-0.33%GBPHKD+0.32%GBPMXN-0.28%AUDUSD+0.28%EURNZD-0.28%GBPCAD-0.26%GBPZAR-0.26%NZDCHF+0.26%USDCAD-0.25%EURUSD-0.24%AUDNZD+0.23%EURGBP-0.23%NOKJPY+0.23%PLNJPY+0.21%EURZAR-0.21%USDCHF+0.21%NZDCAD-0.20%GBPCHF+0.19%NZDJPY+0.19%SGDJPY+0.18%NZDSGD+0.16%USDILS+0.16%AUDSGD+0.15%NZDMXN+0.15%USDSEK-0.14%USDJPY+0.14%EURJPY-0.13%USDDKK-0.13%USDNOK-0.12%EURHKD+0.11%GBPJPY+0.11%USDPLN-0.10%AUDNOK+0.10%USDCNH-0.10%AUDDKK+0.09%CHFSGD+0.08%CHFJPY-0.07%USDMXN-0.07%USDSGD-0.07%GBPNZD-0.06%EURSGD+0.05%EURCHF-0.05%NZDUSD+0.05%USDTHB+0.04%USDCOP-0.04%EURCNH+0.04%EURCZK+0.03%EURSEK-0.03%CHFNOK+0.02%AUDCAD+0.02%EURPLN+0.01%GBPUSD-0.01%EURDKK-0.01%USDHKD+0.01%EURNOK0.00%GBPSGD0.00%CHFSEK0.00%XPTUSD+2.04%GAGUSD+1.71%XAGUSD+1.71%HG1+1.44%GAUUSD+1.11%XAUUSD+1.11%UKOIL-1.04%USOIL-0.85%S1+0.74%COTTON+0.53%C1+0.50%W1+0.35%BTCUSD-1.08%ETHUSD+11.79%USDTUSD-0.05%XRPUSD+5.55%SOLUSD+1.82%TRXUSDT-0.91%ZECUSDT-8.35%DOGEUSD+5.25%XMRUSDT-2.57%LINKUSD+7.35%XLMUSD-2.95%BCHUSDT-7.05%LTCUSD+1.20%UNIUSD-6.89%SUIUSD-6.32%HBARUSDT-1.56%TONUSD+18.86%TAOUSDT-6.02%AAVEUSD-4.48%DOTUSDT+2.92%ICPUSDT-6.55%ONDOUSDT+1.49%WLDUSDT-5.81%JUPUSDT-2.55%ARBUSDT-4.80%ATOMUSDT+6.98%STXUSDT+6.42%INJUSDT-6.74%FETUSDT-4.14%PYTHUSDT+10.14%TIAUSDT+9.94%SEIUSDT-3.41%IMXUSDT+7.40%GRTUSDT-3.76%OPUSDT-0.41%WIFUSDT-8.72%IOTAUSDT-5.68%AXSUSDT-5.67%POLUSDT-2.74%FARTCOINUSDT+2.08%EOSUSDT-0.69%DYDXUSDT-0.09%GALAUSDT-4.26%ORDIUSDT-6.25%RONINUSDT-4.25%NOTUSDT-5.84%
ST

Summit Therapeutics Inc. (SMMT)

NASDAQ • Healthcare

$17.17
-$0.77 (-4.3%)
Market closed

Last close at October 8, 2026 at 20:00 UTC

Open$17.61
Day Range$16.8 - $17.64
Avg. Volume (3M)7.3M
Market Cap$13.6B
52 Week Range
$12.07$29.23
Next EarningsIn 10 daysOct 19, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$856M
EPS (TTM)
-$1.12
ROA (TTM)
-113.81%
Current Ratio
6.96

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-182.5%Q1 2026-$0.29
+27.3%Q2 2026-$0.24
-2.0%Q3 2026-$0.28
Next

Oct 19

in 10 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -2.0%

Summit Therapeutics’ loss per share trailed expectations in the second fiscal quarter of 2026, based on preliminary results reported July 23, 2026, with EPS of -$0.28 trailing the -$0.27 estimate by -$0.01. The quarter’s results reflected the company’s clinical-stage focus, with its pipeline centered on anti-infective development including the ridinilazole program for Clostridioides difficile infection. On a GAAP basis, operating income was a loss of roughly $220.5 million, while net income was a loss of about $215.7 million, up ~48% from a loss of roughly $412.2 million a year ago. Cash flow from operations was negative at about $167.8 million. For the next period, consensus calls for EPS of -$0.28 on revenue of $71,429.00.

Next report — what to expect

Summit Therapeutics Inc. (SMMT) is scheduled to report earnings on October 19, 2026. Wall Street is looking for consensus EPS of -$0.28 on revenue of $71,429.00. In recent history, the company has beaten EPS in 3 of its 8 most recent quarters, making the upcoming print a fresh check on execution versus expectations.

View full earnings history

About Summit Therapeutics Inc.

Summit Therapeutics Inc. is a NASDAQ-listed biotechnology company focused on discovering, developing, and commercializing therapeutic solutions. In qualitative terms, it is a clinical-stage healthcare business built around anti-infective drug development, with a pipeline centered chiefly on Clostridioides difficile infection, or CDI, including the Phase III program ridinilazole.

Name
Summit Therapeutics Inc.
CEO
Robert W. Duggan
Website
www.smmttx.com
Industry
Healthcare
Year Founded
2003
Employees
265

Today's Snapshot

AI-generated

SMMT closed 4.3% lower at 17.17, while its sector was flat. Shares changed hands at about two-thirds of its usual level. Summit Therapeutics received a $2 billion investment from AstraZeneca, the drugmaker.

Trading Volume

Below 10d avg (8.9M)

6.1M

vs S&P 500 Today

Strong Underperformance

-3.81%

Updated: October 8, 2026 at 20:11 UTC

Technical Indicators

5 Buy3 Neutral0 Sell
SMMT shows a favorable technical alignment with the price above key short- and long-term moving averages and ADX indicating a developing trend, while momentum measures are modestly positive. Volume-based OBV is supportive and the MACD is constructive, even as ATR signals relatively elevated volatility and the classic pivot sits above the market as near-term resistance. Bollinger bands are neutral. Technical takeaway: Trend strength and moving-average structure favor a bullish bias, tempered by higher volatility and nearby pivot resistance.
All signals
  • EMA (5 indicators)$15.90 - $17.05
    Buy
  • RSI (14)55.19
    Neutral
  • Stochastic %K (14, 3, 3)58.74
    Neutral
  • MACD Level (12, 26)0.45
    Neutral

Peers & Related Assets

IBRXImmunityBio, Inc.
$9.91+1.6%
ENTAEnanta Pharmaceuticals, Inc.
$12.1-2.2%
PALIPalisade Bio, Inc.
SPROSpero Therapeutics, Inc.
MCRBSeres Therapeutics, Inc.
TRAWTraws Pharma, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.